Immunic
IMUX
59 hedge funds and large institutions have $36.9M invested in Immunic in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 13 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
6% more capital invested
Capital invested by funds: $34.8M → $36.9M (+$2.16M)
2% more funds holding
Funds holding: 58 → 59 (+1)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0.02% less ownership
Funds ownership: 5.61% → 5.58% (-0.02%)
90% less call options, than puts
Call options by funds: $55K | Put options by funds: $545K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$4.69M |
| 2 |
Millennium Management
New York
|
+$989K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$806K |
| 4 |
RI
RTW Investments
New York
|
+$804K |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$782K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$2.52M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$931K |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$885K |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$885K |
| 5 |
CAC
Cowen and Company
New York
|
-$804K |
IMUX Hedge Fund Activity: Q1 2023 in Review
59 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2023, worth a combined $36.9M — up 6.2% from $34.8M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMUX positions and 13 closed out — a net gain of 1 holder — while 16 added to existing stakes and 14 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $4.69M. The largest seller was Commodore Capital, exiting entirely with an estimated $2.52M sold.
- 59 institutional investors held Immunic (IMUX) as of Q1 2023, up from 58 in Q4 2022.
- Funds reported $36.9M of Immunic stock for Q1 2023, up 6.2% quarter-over-quarter.
- 14 funds opened new Immunic positions in Q1 2023 and 13 closed out, a net change of +1 holder.
- The largest Immunic buyer in Q1 2023 was Deep Track Capital, an estimated $4.69M added.
- The largest Immunic seller in Q1 2023 was Commodore Capital, an estimated $2.52M sold.
Based on aggregated 13F filings for Q1 2023.